|本期目录/Table of Contents|

[1]童宁.阿尔茨海默病患者血清CD33 水平及其临床意义[J].慢性病学杂志,2018,(6):694-697.
　TONG Ning.Analysis of the expression and diagnostic value of CD33 in Alzheimer's disease[J].,2018,(6):694-697.
点击复制

阿尔茨海默病患者血清CD33 水平及其临床意义(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
期数:
2018年6期
页码:
694-697
栏目:
论　著
出版日期:
2018-06-27

文章信息/Info

Title:
Analysis of the expression and diagnostic value of CD33 in Alzheimer's disease
作者:
童宁
山东菏泽市立医院神经内科，山东菏泽274000
Author(s):
TONG Ning
Department of Neurology, Heze Municipal Hospital, Heze, Shandong 274000, China Corresponding author: TONG Ning, E-mail: iuyuepin-g@163.com
关键词:
CD33; 阿尔茨海默病; C 反应蛋白; 同型半胱氨酸
Keywords:
CD33;  Alzheimer's disease;  C reactive protein;  Homocysteine
分类号:
R749.16
DOI:
-
摘要:
目的探讨CD33 在阿尔茨海默病（AD） 中表达情况及诊断价值，为临床诊断提供参考。方法选择 山东菏泽市立医院收治的73例AD 患者作为AD 组，30例帕金森病（PD） 患者作为PD 组，以及30例健康受试者 作为对照组，检测并比较各组受试者血清C 反应蛋白（CRP）、同型半胱氨酸（HCY）、CD33 表达情况，其中 CRP 和HCY 采用全自动生化分仪检测，CD33 采用流式细胞仪检测，分析CD33 与CRP、HCY 相关性，并采用 受试者工作特征（ROC） 曲线分析CD33对AD 诊断价值。结果三组受试者血清CRP 和HCY 水平比较，差异 有统计学意义（P<0.05）。AD 组患者血浆CD33+单核细胞比率明显低于PD 组与对照组的，差异有统计学意义 （P<0.05）；而PD 组与对照组CD33+表达情况比较，差异无统计学意义（P>0.05）。AD 患者CD33+表达率与 CRP、HCY 水平呈显著正相关关系（r=0.682、0.610，P<0.05）。在PD 患者中，CD33对AD 诊断曲线下面积为 0.771。在对照组中，CD33 对AD 诊断曲线下面积为0.908。结论CD33 对阿尔茨海默病患者的影响可能与炎 症反应有关，CD33对AD 患者具有着一定的诊断价值，可作为一种潜在的AD 诊断生物标志物。
Abstract:
Objective To investigate and analyze the expression and diagnostic value of CD33 in Alzheimer's disease （AD） . Methods Totally 73 cases of AD patients in Heze Municipal Hospital were selected as AD group, and 30 cases of Parkinson's disease （PD） were selected as PD group and 30 healthy subjects were selected as control group. The serum C reactive protein （CRP） , homocysteine （HCY） and CD33 levels were detected and compared among the three groups. CRP and HCY were detected by fully automated biochemical analyzer. CD33 was detected by flow cytometry. The correlation between CD33 and CRP and HCY was analyzed. The value of CD33 on diagnosing AD was analyzed by using the subjects' working characteristics （ROC） curve. Results There were significant differences of serum CRP and HCY in the three groups （P<0.05） , and both CRP and HCY levels in AD group were higher than those in PD group and control group. The plasma CD33+ positive monocyte ratio in AD group was significantly lower than that in PD group and control group （P<0.05） , but there was no difference in CD33 + expression between PD group and control group （P>0.05） . There were significant positive correlations between expression of CD33+ and levels of CRP （r=0.682, P<0.05） and HCY in AD patients （r=0.610, P<0.05） . In PD patients, the area under the ROC curve for the diagnosis of AD was 0.771, and in the control group, the area was 0.908. Conclusion CD33 in AD patients may be related to inflammatory reaction. CD33 has certain diagnostic value for AD patients, so it can be used as a potential biomarker for AD diagnosis.

参考文献/References:

[1] 童宁.血液CD33的检测对阿尔茨海默病的诊断作用[J].中国医师 杂志,2015,17(9):1385-1387.[2] Serrano- Pozo A, Betensky RA, Frosch MP, et al. Plaque-Associated Local Toxicity Increases over the Clinical Course of Alzheimer Disease [J]. Am J Pathol, 2016, 186(2):375-384. [3] 郑文选,郑磊,袁栋才,等.载脂蛋白Eε4等位基因在阿尔茨海默病 诊断及治疗中研究进展[J].中国老年学杂志,2017,37(14):3636- 3637. [4] Bushra Imtiaz, Marjo Tuppurainen, Toni Rikkonen, et al. Postmenopausal hormone therapy and Alzheimer disease: A prospective cohort study [J]. Neurology, 2017,88(11): 1062-1068. [5] Aschenbrenner AJ, Balota DA, Fagan AM, et al. Alzheimer Disease Cerebrospinal Fluid Biomarkers Moderate Baseline Differences and Predict Longitudinal Change in Attentional Control and Episodic Memory Composites in the Adult Children Study [J]. J Int Neuropsychol Soc, 2015,21 (8):573-583. [6] 季娜,郑欣宁,张凤华,等. 血液中Aβ1-42 和P-tau- 181 对阿尔 茨海默病临床诊断的应用价值[J].医学与哲学,2017,38(22):38- 40,48. [7] 崔凯,张勤,陈淅泠,等.阿尔茨海默病伴睡眠障碍患者ApoE 基因 多态性及血清Lp- PLA2 水平研究[J]. 实用医学杂志,2017,33 (23):3959-3962. [8] Rawan Tarawneh, Gina D’ Angelo, Dan Crimmins, et al. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease [J]. JAMA Neurol, 2016,73(5):561-571. [9] Rajan KB, Wilson RS, Weuve J, et al. Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia [J]. Neurology, 2015,85(10):898-904. [10] 陈李芳,张璐,韩漫夫,等.miRNA- 34a、miRNA- 34c、miRNA- 135a在轻度认知障碍及阿尔茨海默病早期诊断中的应用研 究[J].中国医师杂志,2017,19(5):683-686. [11] 林花,黄文,叶飚,等.早发性家族性阿尔茨海默病一家系早老素- 1 基因突变的研究[J]. 中华医学遗传学杂志,2016,33(3):324- 327. [12] Hsu DC, Marshall GA. Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward [J]. Curr Alzheimer Res, 2017,14(4):426-440. [13] Gooblar J, Roe CM, Selsor NJ, et al. Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results [J]. JAMA Neurol, 2015, 72(12):1484. [14] 罗庆新,罗星星,陈家强,等.脑脊液磷酸化tau 蛋白在阿尔茨海默 病诊断中的应用[J]. 检验医学与临床,2016,13(13):1772-1773, 1777. [15] Serranopozo A, Qian J, Monsell SE, et al. APOEε2 is associated with milder clinical and pathological Alzheimer's disease [J]. Ann Neurol, 2015,77(6):917–929. [16] 庄海,邹海强,徐武华,等. 阿尔茨海默病早期生物学诊断标志物 研究进展[J].中华神经医学杂志,2013,12(3):314-317. [17] Day GS, Musiek ES, Roe CM, et al. Phenotypic Similarities Between Late- Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single- Family Case- Control Study [J]. JAMA Neurol, 2016,73(9):1125–1132 [18] 吕继辉,赫荣乔,李文杰,等. 尿甲醛在阿尔茨海默病诊断中的价 值及影响因素[J].中华行为医学与脑科学杂志,2017,26(7):620- 623. [19] 王琪,秦伟,董静,等.家族性阿尔茨海默病淀粉样前体蛋白I716T 基因突变[J].中华神经科杂志,2017,50(1):24-27. [20] 赵进,蔡兆伟,管峰,等. 阿尔茨海默病与PRNP 突变体小鼠动物 模型[J].中国实验动物学报,2016,24(5):541-545.

备注/Memo

备注/Memo:
基金项目：荷泽市科学技术项目（2017 第071 号） 作者简介：童宁，本科，主治医师，研究方向：脑血管疾病，神经 通信作者：童宁，E-mail：liuyuepin_g@163.com
更新日期/Last Update: 2018-06-28